PNPLA3 Inhibition Increases Cardiovascular Risk via LDL-C and Total Cholesterol Mediation

Overview

Genetically predicted inhibition of PNPLA3 significantly raises the risk of major cardiovascular diseases including coronary atherosclerosis, coronary heart disease, and myocardial infarction. Blood low-density lipoprotein cholesterol (LDL-C) and total cholesterol (TC) mediate a substantial proportion of these increased risks.

Background

Metabolic dysfunction–associated steatotic liver disease (MASLD) affects approximately 25% to 30% of the global population and is linked to increased risks of type 2 diabetes, cardiovascular disease, and mortality. PNPLA3 genetic variants, particularly the I148M polymorphism, are strongly associated with MASLD and related liver complications. ARO-PNPLA3, an RNA interference drug targeting PNPLA3, has shown promise in reducing liver fat but long-term cardiovascular safety remains unclear. Mendelian randomization (MR) offers a method to investigate causal relationships between PNPLA3 inhibition and cardiovascular outcomes.

Data Highlights

Key Findings

• Genetically predicted PNPLA3 inhibition increases risk of coronary atherosclerosis, coronary heart disease, and myocardial infarction with odds ratios around 1.14 to 1.16.
• Suggestive increased risks were also observed for heart failure and atrial fibrillation.
• LDL-C and total cholesterol mediate approximately 14% to 30% of the increased cardiovascular risk associated with PNPLA3 inhibition.
• PNPLA3 inhibition reduces liver fat but may have unintended adverse cardiovascular effects.
• Mendelian randomization validates the causal link between PNPLA3 inhibition and cardiovascular disease risk.

Clinical Implications

Clinicians should be aware that therapies targeting PNPLA3 to reduce liver fat may increase cardiovascular risk, partly mediated by elevations in LDL-C and total cholesterol. Monitoring lipid profiles and cardiovascular status is advisable in patients receiving PNPLA3 inhibitors. These findings highlight the importance of balancing liver benefits with cardiovascular safety in future clinical trials.

Conclusion

PNPLA3 inhibition, while effective in reducing hepatic fat, is associated with increased risk of major cardiovascular diseases mediated in part by lipid alterations. Careful evaluation of cardiovascular outcomes is essential in the development of PNPLA3-targeted therapies.

References

1. Haas et al 2022 -- GWAS of liver fat percentage using MRI and machine learning
2. Arrowhead Pharmaceuticals 2021 -- Phase 1 trial of ARO-PNPLA3 in MASH
3. Mendelian Randomization methodology references